Loading
Latest filing published 01 Jul 2025 for VistaGen Therapeutics, Inc., €11k.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Shawn Singh (chief executive) discloses dealings in 2 companies, chiefly VistaGen Therapeutics, Inc. and Echo Therapeutics, Inc. Between 14 September 2007 and 30 June 2025, the trades on record add up to 22 filings.
The open-market record is one-sided, with 1 purchase worth €101k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 14 share grants and 7 option exercises.
The newest entry dates from 1 July 2025: a share grant of €11k, in VistaGen Therapeutics, Inc. The last insider purchase was made public on 18 August 2022, 1,530 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations